08:21 AM EDT, 07/28/2025 (MT Newswires) -- Alterity Therapeutics ( ATHE ) said Monday that phase 2 data for ATH434 in patients with multiple system atrophy showed that the oral agent conferred a clinical benefit on areas of impairment in MSA and stabilized key biomarkers.

Results from the trial showed that ATH434 reduced disease progression by about 50% compared with historical controls over 12 months, the company said, adding that 30% of participants reported stable neurological symptoms throughout the study.

Alterity said that of the 10 participants in the study, two were discontinued due to progression of multiple system atrophy, and one other patient was discontinued for an unrelated adverse effect.

The company also said that a change in brain volume, a key biomarker endpoint in the study, decreased on average, which was comparable with those observed in participants in the 75 mg dose group of study 201.

Shares of Alterity were down over 19% in recent premarket trading.